Hyperhomocysteinemia is thought to cause ischemic strokes. We report two middle-aged widowers with frequent recurrences of small-artery strokes, two capsular infarcts and a thalamic hemorrhage in one patient, and two thalamic and pontine infarcts in the other. Blood tests following the final stroke showed hyperhomocysteinemia and methylenetetrahydrofolate reductase C677T gene mutation, with low concentration of vitamin B6. Multivitamin supplementation normalized plasma homocysteine levels in both patients. Hyperhomocysteinemia is treatable; therefore, serum homocysteine should be measured as a potential risk factor for stroke recurrence in relatively young patients with recurrent small-artery infarctions or hemorrhage, especially those with insufficient lifestyle factors. 
Introduction
According to recent meta-analyses, elevation of plasma homocysteine (Hcy) level is associated with an increased risk of ischemic stroke (1, 2) . Among stroke subtypes, hyperhomocysteinemia (hyper-Hcy) predisposes to largeartery atherosclerosis including carotid stenosis (3) (4) (5) . Patients with small-artery infarction are also reported to have higher serum Hcy levels than control patients (4) (5) (6) . Although hyper-Hcy does not seem to associate with embolic stroke (4, 5) , it conveys an independent risk for left atrial thrombus formation in stroke patients with nonvalvular atrial fibrillation (7) . The relationship between hyper-Hcy and hemorrhagic stroke has not been clarified. Boysen et al (8) recently demonstrated that elevated serum Hcy is an independent risk factor for recurrent ischemic strokes based on a prospective study of 1,039 patients.
Methylenetetrahydrofolate reductase (MTHFR) serves as an enzyme for conversion of dietary folate to 5-methyltetrahydrofolate and a methyl donor requires the remethylation of Hcy to methionine in vivo (1) . Although the MTHFR C677T gene mutation, a common polymorphism in this gene, increases plasma Hcy levels (9), the mutation has not been reported as a consistent risk factor for stroke (1, 10) . MTHFR TT genotype seems to be an independent risk factor for silent brain infarction and white matter lesions in the general Japanese population (11) .
We report here two middle-aged men with hyper-Hcy and MTHFR TT genotype who had repeated lacunar infarctions and ganglionic hemorrhage under good management of other risk factors except for hyper-Hcy. Multivitamin supplementation was successful for management of hyper-Hcy.
Case Reports

Patient 1
A 53-year-old normotensive clerk developed strokes 3 times during 5 months, and was admitted to our hospital for the third stroke. He had a 30-year history of smoking before quitting after the first stroke. After the death of his wife 4 years previously, he lived alone and often dined on box lunches and noodles. Right hemiparesis was the symptom of the former two ischemic strokes, which occurred at a onemonth interval. Left corona radiata and left basal ganglia were the culprit lesions. Oral administration of aspirin (81 mg/day) was started after the first stroke, and ticlopidine (200 mg/day) was added after the second. One evening 4 months after the second stroke, he suddenly noticed dysesthesia in his right hand, and the symptom spread into the right side of his body within an hour. When he visited our hospital the next morning, blood pressure was 140/82 mmHg, and pulse rate was regular at 60/min. He had a moderate paresis of the right limbs with accelerated deep tendon reflexes. A new neurological sign was the decreased perception of touch, pain and temperature on the right side of the face and right limbs. Cranial MRI revealed a fresh hematoma in the left thalamus and small old infarcts in the left basal ganglia and corona radiata (Fig. 1) . Cranial MRA did not show stenosis of arteries. On blood testing, parameters for common diseases including lipids and hemoglobin A1c were normal except for increased level of Hcy (22.5 mol/l). Among serum vitamins, B12 (320 ng/l) and folate (3.3 g/l) were within normal levels, and B6 was slightly decreased (5.9 g/l). Polymerase chain reaction DNA amplification was performed using whole blood lymphocytes, and MTHFR TT genotype was documented. Cardiac investigations and hemostatic tests did not show any evidence for embolic stroke. Ambulatory blood pressure monitoring showed normotension without morning surge.
Oral supplementation of vitamin B6 (30 mg/day) did not change the plasma level of Hcy (Fig. 2) . Addition of vitamin B12 (1.5 mg/day) and folate (15 mg/day) brought the Hcy level down to normal. There have been no recurrent strokes for a period of more than a year. intake of vegetables, daily alcohol consumption of 500 ml of spirits, and a previous history of smoking, felt a tingle in his left arm when he awoke one morning, and visited our hospital. He had repeated pure sensory strokes due to the left thalamic infarction at 6 years and 2 years before; in addition to silent infarcts in the left pons and right thalamus indicated 7 years before. Oral administration of ticlopidine (200 mg/ day) was continued after the first stroke. Although he was hypertensive in the previous medical examination, he kept normotensive without use of antihypertensives after the first stroke. On admission, his blood pressure was 150/80 mmHg, and pulse rate a regular 80/min. He was neurologically intact except for dysesthesia in the left arm and chronic hypesthesia in the right limbs. Cranial MRI delineated a fresh infarct in the right tegmentum of the pons and small old infarcts in the left pons, both thalami, and both basal ganglia (Fig. 1) (Fig. 2) . He has been free from stroke for a period of more than a year.
Discussion
The main aspects of this report are that middle-aged men with uncontrolled hyper-Hcy and MTHFR TT genotype had repeated small-artery infarctions and hemorrhage at short intervals, and further that multivitamin supplementation of B6, B12, and folate returned the relatively high plasma Hcy levels to normal.
Although plasma Hcy levels were not measured before the final stroke, the levels might have been high before the first stroke because of the existence of MTHFR gene mutation. A deficiency of the dietary vitamins required for metabolism of Hcy in vivo might have resulted from the insufficiencies of their dietary habits, which are quite common for middle-aged Japanese men living without wives. Population-based studies reported that plasma Hcy levels were positively related with male gender and alcohol consumption (12, 13) . Previous smoking habit and hypertension were other possible risk factors for the strokes. However, because these two factors were well controlled after the first strokes, hyper-Hcy seemed to be an essential risk factor for stroke recurrence in the present patients. Hcy levels went far beyond the reported mean values for 1,487 stroke patients (13.51 mol/l versus 11.07 mol/l for nonstroke subjects) in a meta-analysis (1) . Among the three small-population studies regarding the positive association of hyper-Hcy with lacunar infarction (4-6), two indicated a weak association (4, 6) , while the other indicated that the association was a little stronger than that with large-artery atherosclerosis (5) . In addition, hyper-Hcy has been suggested to associate with subcortical vascular encephalopathy (14, 15) . Although the pathology of deep perforating arteries and subcortical microvessels may differ, these findings suggest that hyper-Hcy contributes to small artery diseases in a fashion different from atherosclerosis, possibly including the formation of microatheroma. A positive relationship between hyper-Hcy and hemorrhagic stroke has been reported in children and infants (16, 17) , but not in an adult population. Because ganglionic hemorrhage usually results from the same vascular pathology with lacunar infarction, there might also be a positive association between hyper-Hcy and ganglionic hemorrhage. For Patient 1, intensive antiplatelet therapy might have been a trigger for hemorrhagic stroke. Thus, measurement of plasma Hcy level, and if needed its normalization, appears to be necessary for cryptogenic lacunar infarction before antithrombotic medication.
According to the meta-analysis (2), lowering the Hcy level by 3 mol/l from current levels would reduce the risk of stroke by about 24% (15 to 33%). From the therapeutic results of Patient 1, a single vitamin supplementation is not sufficient, and multivitamin supplementation of B6, B12, and folate seems to be necessary regardless of baseline serum levels. Two large clinical trials on the prevention of recurrent stroke, Vitamin Intervention for Stroke Prevention (VISP) (18) and Vitamins to Prevent Stroke (VITATOPS) (19) , are underway.
In conclusion, hyper-Hcy may be a potential risk factor for recurrent small-artery infarctions and hemorrhage. Serum Hcy should be measured for relatively young patients with recurrent small-artery strokes, especially those with insufficiencies of lifestyle factors; thus the chance of management for this treatable risk factor will not be lost.
